• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

个体化成本效益分析。

Individualized cost-effectiveness analysis.

机构信息

Stanford Prevention Research Center, Department of Medicine, Stanford University School of Medicine, Stanford, California, United States of America.

出版信息

PLoS Med. 2011 Jul;8(7):e1001058. doi: 10.1371/journal.pmed.1001058. Epub 2011 Jul 12.

DOI:10.1371/journal.pmed.1001058
PMID:21765810
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3134464/
Abstract

John Ioannidis and Alan Garber discuss how to use incremental cost-effectiveness ratios (ICER) and related metrics so they can be useful for decision-making at the individual level, whether used by clinicians or individual patients.

摘要

约翰·约安尼季斯和艾伦·加伯讨论了如何使用增量成本效益比（ICER）和相关指标，以便在个体层面上为决策提供有用信息，无论是临床医生还是个体患者使用。

相似文献

1
Individualized cost-effectiveness analysis.个体化成本效益分析。
PLoS Med. 2011 Jul;8(7):e1001058. doi: 10.1371/journal.pmed.1001058. Epub 2011 Jul 12.
2
Cost-effectiveness analysis and capital costs.成本效益分析与资本成本。
Soc Sci Med. 1998 May;46(9):1183-91. doi: 10.1016/s0277-9536(97)10046-6.
3
The concept of cost in the economic evaluation of health care. A theoretical inquiry.医疗保健经济评估中的成本概念：一项理论探究
Int J Technol Assess Health Care. 1994 Fall;10(4):675-82. doi: 10.1017/s0266462300008254.
4
A note on confidence intervals in cost-effectiveness analysis.关于成本效益分析中置信区间的一则注释。
Int J Technol Assess Health Care. 1998 Summer;14(3):467-71. doi: 10.1017/s0266462300011442.
5
Opportunity costs and uncertainty in the economic evaluation of health care interventions.医疗保健干预措施经济评估中的机会成本与不确定性
Health Econ. 2002 Jan;11(1):23-31. doi: 10.1002/hec.641.
6
Cost-effectiveness acceptability curves in the dock: case not proven?码头的成本效益可接受性曲线：尚无定论？
Med Decis Making. 2007 Mar-Apr;27(2):93-5. doi: 10.1177/0272989X07300071.
7
Using cost-effectiveness/cost-benefit analysis to allocate health resources: a level playing field for prevention?利用成本效益/成本效益分析来分配卫生资源：预防的公平竞争环境？
Am J Prev Med. 1997 Jan-Feb;13(1):18-25.
8
[When is expensive pharmacotherapy good value for the money?].[何时昂贵的药物治疗物有所值？]
Internist (Berl). 2004 Oct;45(10):1189-95. doi: 10.1007/s00108-004-1238-z.
9
Consumption costs and earnings during added years of life - a reply to Nyman.增加的寿命期间的消费成本与收入——对尼曼的回应。
Health Econ. 2006 Mar;15(3):315-7; discussion 319-22. doi: 10.1002/hec.1065.
10
Cost effectiveness/utility analyses. Do current decision rules lead us to where we want to be?成本效益/效用分析。当前的决策规则能引领我们实现目标吗？
J Health Econ. 1992 Oct;11(3):279-96. doi: 10.1016/0167-6296(92)90004-k.

引用本文的文献

1
Understanding healthcare efficiency-an AI-supported narrative review of diverse terminologies used.理解医疗保健效率——对所使用的各种术语的人工智能支持的叙述性综述。
BMC Med Educ. 2025 Mar 20;25(1):408. doi: 10.1186/s12909-025-06983-5.
2
Minimal differences observed when comparing the morphological profiling of microglia obtained by confocal laser scanning and optical sectioning microscopy.在比较通过共聚焦激光扫描和光学切片显微镜获得的小胶质细胞形态特征时，观察到的差异极小。
Front Neuroanat. 2025 Jan 3;18:1507140. doi: 10.3389/fnana.2024.1507140. eCollection 2024.
3
Challenges around quantifying uncertainty in a holistic approach to hard-to-heal wound management: Health economic perspective.整体方法治疗难愈性伤口管理中量化不确定性的挑战：健康经济学视角。
Int Wound J. 2023 Mar;20(3):792-798. doi: 10.1111/iwj.13924. Epub 2022 Sep 8.
4
The Online Elicitation of Personal Utility Functions (OPUF) tool: a new method for valuing health states.在线个人效用函数诱导（OPUF）工具：一种评估健康状态的新方法。
Wellcome Open Res. 2022 Jan 14;7:14. doi: 10.12688/wellcomeopenres.17518.1. eCollection 2022.
5
COVID outcome prediction in the emergency department (COPE): using retrospective Dutch hospital data to develop simple and valid models for predicting mortality and need for intensive care unit admission in patients who present at the emergency department with suspected COVID-19.急诊科 COVID 结局预测（COPE）：利用荷兰医院回顾性数据，为因疑似 COVID-19 而到急诊科就诊的患者建立简单且有效的死亡率和需要入住重症监护病房的预测模型。
BMJ Open. 2021 Sep 16;11(9):e051468. doi: 10.1136/bmjopen-2021-051468.
6
How to assess the value of low-value care.如何评估低价值医疗的价值。
BMC Health Serv Res. 2020 Nov 2;20(1):1000. doi: 10.1186/s12913-020-05825-y.
7
Continuous Glucose Monitoring as a Matter of Justice.连续血糖监测的公正性问题。
HEC Forum. 2021 Dec;33(4):345-370. doi: 10.1007/s10730-020-09413-9.
8
Scientific challenges for precision public health.精准公共卫生面临的科学挑战。
J Epidemiol Community Health. 2020 Apr;74(4):311-314. doi: 10.1136/jech-2019-213311. Epub 2020 Jan 23.
9
The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement: Explanation and Elaboration.预测治疗效果异质性的方法（PATH）声明：解释和说明。
Ann Intern Med. 2020 Jan 7;172(1):W1-W25. doi: 10.7326/M18-3668. Epub 2019 Nov 12.
10
Economic Analysis of Hospital Palliative Care: Investigating Heterogeneity by Noncancer Diagnoses.医院姑息治疗的经济分析：按非癌症诊断调查异质性
MDM Policy Pract. 2019 Sep 10;4(2):2381468319866451. doi: 10.1177/2381468319866451. eCollection 2019 Jul-Dec.

本文引用的文献

1
Industry involvement and baseline assumptions of cost-effectiveness analyses: diagnostic accuracy of the Papanicolaou test.行业参与和成本效益分析的基本假设：巴氏涂片检查的诊断准确性。
CMAJ. 2011 Apr 5;183(6):E337-43. doi: 10.1503/cmaj.101506. Epub 2011 Mar 14.
2
High-value, cost-conscious health care: concepts for clinicians to evaluate the benefits, harms, and costs of medical interventions.高值、成本意识的医疗保健：临床医生评估医疗干预措施的获益、危害和成本的概念。
Ann Intern Med. 2011 Feb 1;154(3):174-80. doi: 10.7326/0003-4819-154-3-201102010-00007.
3
Regulating direct-to-consumer genetic tests: what is all the fuss about?直接面向消费者的基因检测的监管：有什么好大惊小怪的？
Genet Med. 2011 Apr;13(4):295-300. doi: 10.1097/GIM.0b013e3181f69dd2.
4
Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal.评估和报告临床试验中治疗效果的异质性：建议。
Trials. 2010 Aug 12;11:85. doi: 10.1186/1745-6215-11-85.
5
Screening for postnatal depression in primary care: cost effectiveness analysis.基层医疗中产后抑郁症的筛查：成本效益分析。
BMJ. 2009 Dec 22;339:b5203. doi: 10.1136/bmj.b5203.
6
Effectiveness and cost-effectiveness of vaccination against pandemic influenza (H1N1) 2009.接种 2009 年大流行性流感（H1N1）疫苗的效果和成本效益。
Ann Intern Med. 2009 Dec 15;151(12):829-39. doi: 10.7326/0003-4819-151-12-200912150-00157.
7
Evaluation of modernisation of adult critical care services in England: time series and cost effectiveness analysis.英格兰成人重症监护服务现代化评估：时间序列与成本效益分析
BMJ. 2009 Nov 11;339:b4353. doi: 10.1136/bmj.b4353.
8
Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.采用对症治疗、改善病情抗风湿药或生物制剂治疗极早期类风湿关节炎：一项成本效益分析。
Ann Intern Med. 2009 Nov 3;151(9):612-21. doi: 10.7326/0003-4819-151-9-200911030-00006.
9
Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States.美国将男孩纳入人乳头瘤病毒疫苗接种计划的成本效益分析。
BMJ. 2009 Oct 8;339:b3884. doi: 10.1136/bmj.b3884.
10
Public health impact and cost effectiveness of mass vaccination with live attenuated human rotavirus vaccine (RIX4414) in India: model based analysis.印度使用减毒活人类轮状病毒疫苗（RIX4414）进行大规模疫苗接种的公共卫生影响和成本效益：基于模型的分析
BMJ. 2009 Sep 25;339:b3653. doi: 10.1136/bmj.b3653.